Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

Status:
Completed

Trial end date:
2005-06-01

Target enrollment:

Participant gender:

Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas

Phase 1

Celgene Corporation